Heron Therapeutics, Inc. (HRTX)
USD 1.87
(-10.95%)
USD 1.87
(-10.95%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 172.55 Million USD | -24.14% |
| 2022 | 227.45 Million USD | -11.89% |
| 2021 | 258.15 Million USD | -8.0% |
| 2020 | 280.61 Million USD | -4.89% |
| 2019 | 295.04 Million USD | 26.14% |
| 2018 | 233.89 Million USD | 5.96% |
| 2017 | 220.73 Million USD | 28.22% |
| 2016 | 172.15 Million USD | 77.62% |
| 2015 | 96.92 Million USD | 29.99% |
| 2014 | 74.56 Million USD | 36.92% |
| 2013 | 54.45 Million USD | 128.51% |
| 2012 | 23.83 Million USD | 103.54% |
| 2011 | 11.7 Million USD | 4.21% |
| 2010 | 11.23 Million USD | -2.33% |
| 2009 | 11.5 Million USD | -51.7% |
| 2008 | 23.81 Million USD | -0.96% |
| 2007 | 24.04 Million USD | 27.47% |
| 2006 | 18.86 Million USD | 36.06% |
| 2005 | 13.86 Million USD | -5.82% |
| 2004 | 14.72 Million USD | 28.45% |
| 2003 | 11.46 Million USD | 12.42% |
| 2002 | 10.19 Million USD | -4.28% |
| 2001 | 10.65 Million USD | 50.86% |
| 2000 | 7.05 Million USD | -37.53% |
| 1999 | 11.3 Million USD | -4.24% |
| 1998 | 11.8 Million USD | -4.07% |
| 1997 | 12.3 Million USD | -24.54% |
| 1996 | 16.3 Million USD | 9.4% |
| 1995 | 14.9 Million USD | -6.29% |
| 1994 | 15.9 Million USD | -14.97% |
| 1993 | 18.7 Million USD | 88.89% |
| 1992 | 9.9 Million USD | 73.68% |
| 1991 | 5.7 Million USD | -3.39% |
| 1990 | 5.9 Million USD | -20.27% |
| 1989 | 7.4 Million USD | -5.13% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 31.02 Million USD | -10.25% |
| 2024 Q2 | 31.95 Million USD | 2.99% |
| 2023 Q3 | 38.15 Million USD | -29.35% |
| 2023 Q4 | 34.56 Million USD | -9.4% |
| 2023 Q2 | 54 Million USD | 17.86% |
| 2023 FY | 172.55 Million USD | -24.14% |
| 2023 Q1 | 45.82 Million USD | 21.37% |
| 2022 FY | 227.45 Million USD | -11.89% |
| 2022 Q1 | 75.02 Million USD | 18.61% |
| 2022 Q2 | 60.95 Million USD | -18.76% |
| 2022 Q3 | 53.72 Million USD | -11.86% |
| 2022 Q4 | 37.75 Million USD | -29.72% |
| 2021 Q2 | 68.39 Million USD | 8.68% |
| 2021 Q1 | 62.92 Million USD | -13.22% |
| 2021 Q3 | 63.58 Million USD | -7.02% |
| 2021 Q4 | 63.25 Million USD | -0.53% |
| 2021 FY | 258.15 Million USD | -8.0% |
| 2020 Q4 | 72.5 Million USD | 1.87% |
| 2020 Q3 | 71.17 Million USD | 2.55% |
| 2020 FY | 280.61 Million USD | -4.89% |
| 2020 Q1 | 67.51 Million USD | -14.08% |
| 2020 Q2 | 69.41 Million USD | 2.81% |
| 2019 Q3 | 60.28 Million USD | -19.46% |
| 2019 Q2 | 74.85 Million USD | -7.98% |
| 2019 Q1 | 81.34 Million USD | 18.6% |
| 2019 FY | 295.04 Million USD | 26.14% |
| 2019 Q4 | 78.57 Million USD | 30.34% |
| 2018 Q4 | 68.58 Million USD | 27.03% |
| 2018 Q2 | 50.89 Million USD | -15.76% |
| 2018 FY | 233.89 Million USD | 5.96% |
| 2018 Q1 | 60.42 Million USD | -14.42% |
| 2018 Q3 | 53.99 Million USD | 6.07% |
| 2017 Q4 | 70.6 Million USD | 44.58% |
| 2017 Q1 | 51.74 Million USD | 7.7% |
| 2017 Q2 | 49.55 Million USD | -4.24% |
| 2017 FY | 220.73 Million USD | 28.22% |
| 2017 Q3 | 48.83 Million USD | -1.45% |
| 2016 Q3 | 47.73 Million USD | 10.84% |
| 2016 FY | 172.15 Million USD | 77.62% |
| 2016 Q1 | 33.31 Million USD | 7.25% |
| 2016 Q4 | 48.04 Million USD | 0.66% |
| 2016 Q2 | 43.06 Million USD | 29.28% |
| 2015 Q4 | 31.06 Million USD | 38.1% |
| 2015 FY | 96.92 Million USD | 29.99% |
| 2015 Q2 | 23.01 Million USD | 13.04% |
| 2015 Q1 | 20.36 Million USD | 4.44% |
| 2015 Q3 | 22.49 Million USD | -2.27% |
| 2014 FY | 74.56 Million USD | 36.92% |
| 2014 Q4 | 19.49 Million USD | 2.86% |
| 2014 Q3 | 18.95 Million USD | 0.86% |
| 2014 Q2 | 18.79 Million USD | 8.48% |
| 2014 Q1 | 17.32 Million USD | 25.23% |
| 2013 FY | 54.45 Million USD | 128.51% |
| 2013 Q1 | 12.75 Million USD | 47.8% |
| 2013 Q4 | 13.83 Million USD | 9.22% |
| 2013 Q2 | 15.2 Million USD | 19.27% |
| 2013 Q3 | 12.66 Million USD | -16.73% |
| 2012 Q4 | 8.62 Million USD | 42.52% |
| 2012 FY | 23.83 Million USD | 103.54% |
| 2012 Q3 | 6.05 Million USD | 38.22% |
| 2012 Q2 | 4.38 Million USD | -8.16% |
| 2012 Q1 | 4.76 Million USD | 15.81% |
| 2011 Q1 | 1.71 Million USD | -10.56% |
| 2011 Q4 | 4.11 Million USD | 0.71% |
| 2011 Q2 | 1.79 Million USD | 4.74% |
| 2011 Q3 | 4.08 Million USD | 128.31% |
| 2011 FY | 11.7 Million USD | 4.21% |
| 2010 Q1 | 3.11 Million USD | 40.05% |
| 2010 Q2 | 4.22 Million USD | 35.76% |
| 2010 Q3 | 1.98 Million USD | -52.99% |
| 2010 Q4 | 1.91 Million USD | -3.73% |
| 2010 FY | 11.23 Million USD | -2.33% |
| 2009 Q1 | 2.97 Million USD | -22.72% |
| 2009 Q3 | 2.33 Million USD | -41.37% |
| 2009 Q4 | 2.22 Million USD | -4.64% |
| 2009 FY | 11.5 Million USD | -51.7% |
| 2009 Q2 | 3.97 Million USD | 33.49% |
| 2008 Q4 | 3.85 Million USD | -39.25% |
| 2008 Q1 | 7.22 Million USD | -9.16% |
| 2008 Q2 | 6.4 Million USD | -11.34% |
| 2008 FY | 23.81 Million USD | -0.96% |
| 2008 Q3 | 6.34 Million USD | -0.94% |
| 2007 Q2 | 4.63 Million USD | -24.63% |
| 2007 Q1 | 6.15 Million USD | 7.4% |
| 2007 Q3 | 5.35 Million USD | 15.58% |
| 2007 FY | 24.04 Million USD | 27.47% |
| 2007 Q4 | 7.94 Million USD | 48.37% |
| 2006 Q3 | 3.94 Million USD | -17.56% |
| 2006 Q1 | 4.4 Million USD | 6.85% |
| 2006 FY | 18.86 Million USD | 36.06% |
| 2006 Q2 | 4.78 Million USD | 8.82% |
| 2006 Q4 | 5.72 Million USD | 45.04% |
| 2005 Q2 | 3.9 Million USD | 46.05% |
| 2005 Q4 | 4.11 Million USD | 29.77% |
| 2005 Q3 | 3.17 Million USD | -18.64% |
| 2005 FY | 13.86 Million USD | -5.82% |
| 2005 Q1 | 2.67 Million USD | -30.08% |
| 2004 FY | 14.72 Million USD | 28.45% |
| 2004 Q1 | 3.75 Million USD | 30.7% |
| 2004 Q4 | 3.82 Million USD | 11.83% |
| 2004 Q3 | 3.41 Million USD | -8.3% |
| 2004 Q2 | 3.72 Million USD | -0.9% |
| 2003 FY | 11.46 Million USD | 12.42% |
| 2003 Q3 | 2.5 Million USD | -19.28% |
| 2003 Q4 | 2.87 Million USD | 14.9% |
| 2003 Q2 | 3.1 Million USD | 4.06% |
| 2003 Q1 | 2.98 Million USD | 25.53% |
| 2002 Q3 | 2.67 Million USD | -4.66% |
| 2002 FY | 10.19 Million USD | -4.28% |
| 2002 Q4 | 2.37 Million USD | -11.35% |
| 2002 Q1 | 2.33 Million USD | -27.91% |
| 2002 Q2 | 2.8 Million USD | 20.38% |
| 2001 Q4 | 3.23 Million USD | 15.04% |
| 2001 FY | 10.65 Million USD | 50.86% |
| 2001 Q1 | 2.19 Million USD | -5.75% |
| 2001 Q2 | 2.4 Million USD | 9.94% |
| 2001 Q3 | 2.81 Million USD | 16.81% |
| 2000 FY | 7.05 Million USD | -37.53% |
| 2000 Q3 | 1.66 Million USD | -5.08% |
| 2000 Q2 | 1.75 Million USD | -6.63% |
| 2000 Q4 | 2.32 Million USD | 39.89% |
| 2000 Q1 | 1.87 Million USD | -65.27% |
| 1999 Q1 | 3 Million USD | 7.14% |
| 1999 FY | 11.3 Million USD | -4.24% |
| 1999 Q3 | 2.7 Million USD | -3.57% |
| 1999 Q2 | 2.8 Million USD | -6.67% |
| 1999 Q4 | 5.4 Million USD | 100.0% |
| 1998 Q1 | 2.9 Million USD | -9.38% |
| 1998 FY | 11.8 Million USD | -4.07% |
| 1998 Q2 | 3.2 Million USD | 10.34% |
| 1998 Q4 | 2.8 Million USD | 0.0% |
| 1998 Q3 | 2.8 Million USD | -12.5% |
| 1997 FY | 12.3 Million USD | -24.54% |
| 1997 Q2 | 3.1 Million USD | -3.13% |
| 1997 Q4 | 3.2 Million USD | 14.29% |
| 1997 Q3 | 2.8 Million USD | -9.68% |
| 1997 Q1 | 3.2 Million USD | 3.23% |
| 1996 FY | 16.3 Million USD | 9.4% |
| 1996 Q1 | 4 Million USD | -4.76% |
| 1996 Q3 | 4.6 Million USD | 0.0% |
| 1996 Q2 | 4.6 Million USD | 15.0% |
| 1996 Q4 | 3.1 Million USD | -32.61% |
| 1995 Q2 | 3.7 Million USD | 12.12% |
| 1995 Q4 | 4.2 Million USD | 16.67% |
| 1995 Q3 | 3.6 Million USD | -2.7% |
| 1995 FY | 14.9 Million USD | -6.29% |
| 1995 Q1 | 3.3 Million USD | -21.43% |
| 1994 Q2 | 4.4 Million USD | 15.79% |
| 1994 Q1 | 3.8 Million USD | -26.92% |
| 1994 FY | 15.9 Million USD | -14.97% |
| 1994 Q3 | 3.7 Million USD | -15.91% |
| 1994 Q4 | 4.2 Million USD | 13.51% |
| 1993 Q3 | 4.5 Million USD | -6.25% |
| 1993 FY | 18.7 Million USD | 88.89% |
| 1993 Q4 | 5.2 Million USD | 15.56% |
| 1993 Q1 | 3.3 Million USD | 22.22% |
| 1993 Q2 | 4.8 Million USD | 45.45% |
| 1992 Q1 | 2.3 Million USD | 64.29% |
| 1992 FY | 9.9 Million USD | 73.68% |
| 1992 Q3 | 2.2 Million USD | -15.38% |
| 1992 Q4 | 2.7 Million USD | 22.73% |
| 1992 Q2 | 2.6 Million USD | 13.04% |
| 1991 FY | 5.7 Million USD | -3.39% |
| 1991 Q4 | 1.4 Million USD | 0.0% |
| 1991 Q1 | 1.4 Million USD | -6.67% |
| 1991 Q2 | 1.6 Million USD | 14.29% |
| 1991 Q3 | 1.4 Million USD | -12.5% |
| 1990 FY | 5.9 Million USD | -20.27% |
| 1990 Q1 | 1.3 Million USD | -18.75% |
| 1990 Q3 | 1.5 Million USD | -6.25% |
| 1990 Q4 | 1.5 Million USD | 0.0% |
| 1990 Q2 | 1.6 Million USD | 23.08% |
| 1989 Q1 | - USD | 100.0% |
| 1989 Q3 | 1.5 Million USD | -34.78% |
| 1989 Q4 | 1.6 Million USD | 6.67% |
| 1989 FY | 7.4 Million USD | -5.13% |
| 1989 Q2 | 2.3 Million USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| AbCellera Biologics Inc. | 275.23 Million USD | 37.306% |
| Alkermes plc | 996.24 Million USD | 82.68% |
| Agenus Inc. | 78.18 Million USD | -120.705% |
| Aptorum Group Limited | 10.56 Thousand USD | -1633006.19% |
| Ardelyx, Inc. | 169.93 Million USD | -1.54% |
| Dyadic International, Inc. | 9.15 Million USD | -1785.281% |
| Eton Pharmaceuticals, Inc. | 22.25 Million USD | -675.419% |
| Lantern Pharma Inc. | 17.87 Million USD | -865.198% |
| Inhibikase Therapeutics, Inc. | 6.73 Million USD | -2463.212% |
| Novavax, Inc. | 779.12 Million USD | 77.853% |
| Janux Therapeutics, Inc. | 81.06 Million USD | -112.867% |
| Pyxis Oncology, Inc. | 82.19 Million USD | -109.93% |
| TransCode Therapeutics, Inc. | 19.41 Million USD | -788.605% |
| Ocuphire Pharma, Inc. | 29.6 Million USD | -482.835% |
| Outlook Therapeutics, Inc. | 53.12 Million USD | -224.799% |
| Madrigal Pharmaceuticals, Inc. | 380.49 Million USD | 54.65% |
| Reviva Pharmaceuticals Holdings, Inc. | 24.3 Million USD | -609.906% |
| SELLAS Life Sciences Group, Inc. | 37.86 Million USD | -355.66% |
| Syros Pharmaceuticals, Inc. | 30.77 Million USD | -460.768% |
| Barinthus Biotherapeutics plc | 84.71 Million USD | -103.685% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | -888.452% |
| Xeris Biopharma Holdings, Inc. | 168.43 Million USD | -2.445% |
| Clearside Biomedical, Inc. | 32.71 Million USD | -427.446% |
| C4 Therapeutics, Inc. | 159.78 Million USD | -7.99% |
| Alnylam Pharmaceuticals, Inc. | 1.8 Billion USD | 90.414% |
| AlloVir, Inc. | 180.93 Million USD | 4.631% |
| Arrowhead Pharmaceuticals, Inc. | 445.73 Million USD | 61.288% |
| VYNE Therapeutics Inc. | 29.68 Million USD | -481.342% |
| Bicycle Therapeutics plc | 216.92 Million USD | 20.453% |
| BioXcel Therapeutics, Inc. | 171.9 Million USD | -0.379% |
| ChromaDex Corporation | 56.37 Million USD | -206.061% |
| Chimerix, Inc. | 93.38 Million USD | -84.769% |
| Corbus Pharmaceuticals Holdings, Inc. | 13.9 Million USD | -1140.535% |
| Caribou Biosciences, Inc. | 150.53 Million USD | -14.626% |
| CRISPR Therapeutics AG | 463.49 Million USD | 62.771% |
| Precision BioSciences, Inc. | 92.46 Million USD | -86.62% |
| Fate Therapeutics, Inc. | 254.04 Million USD | 32.077% |
| Fortress Biotech, Inc. | 200.19 Million USD | 13.807% |
| Fortress Biotech, Inc. | 200.19 Million USD | 13.807% |
| HOOKIPA Pharma Inc. | 32.74 Million USD | -426.947% |
| ImmuCell Corporation | 9.61 Million USD | -1694.193% |
| IDEAYA Biosciences, Inc. | 157.81 Million USD | -9.34% |
| Immix Biopharma, Inc. | 16.14 Million USD | -969.034% |
| Incyte Corporation | 1.19 Billion USD | 85.506% |
| Innoviva, Inc. | 132.15 Million USD | -30.57% |
| IO Biotech, Inc. | 91.44 Million USD | -88.701% |
| Jaguar Health, Inc. | 42.01 Million USD | -310.696% |
| Keros Therapeutics, Inc. | 169.27 Million USD | -1.936% |
| Ligand Pharmaceuticals Incorporated | 84.32 Million USD | -104.635% |
| ContextLogic Inc. | 387 Million USD | 55.412% |
| MiMedx Group, Inc. | 229.72 Million USD | 24.887% |
| MEI Pharma, Inc. | 34.78 Million USD | -396.059% |
| NextCure, Inc. | 67.63 Million USD | -155.118% |
| Onconetix, Inc. | 34.9 Million USD | -394.319% |
| Oncternal Therapeutics, Inc. | 12.74 Million USD | -1253.789% |
| Opthea Limited | 191.96 Million USD | 10.113% |
| Psyence Biomedical Ltd. | 2.75 Million USD | -6171.076% |
| Vaxcyte, Inc. | 468.04 Million USD | 63.133% |
| PDS Biotechnology Corporation | 43.04 Million USD | -300.867% |
| Precigen, Inc. | 84.18 Million USD | -104.98% |
| Pharming Group N.V. | 225.49 Million USD | 23.476% |
| Phathom Pharmaceuticals, Inc. | 167.82 Million USD | -2.817% |
| Pieris Pharmaceuticals, Inc. | 72.56 Million USD | -137.789% |
| PureTech Health plc | 144.59 Million USD | -19.334% |
| Rigel Pharmaceuticals, Inc. | 130.26 Million USD | -32.466% |
| Avidity Biosciences, Inc. | 245.15 Million USD | 29.615% |
| Reviva Pharmaceuticals Holdings, Inc. | 24.3 Million USD | -609.906% |
| Sangamo Therapeutics, Inc. | 228.68 Million USD | 24.543% |
| Sol-Gel Technologies Ltd. | 30.85 Million USD | -459.169% |
| Acelyrin, Inc. | 422.06 Million USD | 59.117% |
| Salarius Pharmaceuticals, Inc. | 12.89 Thousand USD | -1338150.349% |
| Summit Therapeutics Inc. | 87.68 Million USD | -96.786% |
| Sensei Biotherapeutics, Inc. | 37.06 Million USD | -365.557% |
| Senti Biosciences, Inc. | 94.7 Million USD | -82.202% |
| Stoke Therapeutics, Inc. | 123.55 Million USD | -39.66% |
| Elevation Oncology, Inc. | 45.44 Million USD | -279.699% |
| Alaunos Therapeutics, Inc. | 29.46 Million USD | -485.544% |
| Telomir Pharmaceuticals, Inc. Common Stock | 3.94 Million USD | -4277.268% |
| Entrada Therapeutics, Inc. | 132.17 Million USD | -30.55% |
| VistaGen Therapeutics, Inc. | 34.08 Million USD | -406.246% |
| Kintara Therapeutics, Inc. | 8.45 Million USD | -1941.818% |
| Wave Life Sciences Ltd. | 181.3 Million USD | 4.825% |
| Seer, Inc. | 110.49 Million USD | -56.172% |
| Verrica Pharmaceuticals Inc. | 70.59 Million USD | -144.432% |
| Aadi Bioscience, Inc. | 93.47 Million USD | -84.593% |
| ESSA Pharma Inc. | 32.13 Million USD | -436.981% |
| GlycoMimetics, Inc. | 39.28 Million USD | -339.233% |
| GT Biopharma, Inc. | 13.57 Million USD | -1171.022% |
| Inhibrx Biosciences, Inc. | 219.83 Million USD | 21.506% |
| Akebia Therapeutics, Inc. | 201.11 Million USD | 14.201% |
| Catalyst Pharmaceuticals, Inc. | 259.42 Million USD | 33.486% |
| Longboard Pharmaceuticals, Inc. | 56.75 Million USD | -204.012% |
| Orchestra BioMed Holdings, Inc. | 54.08 Million USD | -219.072% |
| Alzamend Neuro, Inc. | 9.93 Million USD | -1636.367% |
| Sorrento Therapeutics, Inc. | 403.56 Million USD | 57.242% |
| TRACON Pharmaceuticals, Inc. | 18.92 Million USD | -811.585% |
| Viracta Therapeutics, Inc. | 50.69 Million USD | -240.39% |
| Rocket Pharmaceuticals, Inc. | 259.65 Million USD | 33.546% |
| Aptose Biosciences Inc. | 52.35 Million USD | -229.578% |
| ZyVersa Therapeutics, Inc. | 14.41 Million USD | -1097.429% |
| Soligenix, Inc. | 7.79 Million USD | -2113.578% |
| Century Therapeutics, Inc. | 56.07 Million USD | -207.742% |
| Kura Oncology, Inc. | 165.8 Million USD | -4.071% |
| TScan Therapeutics, Inc. | 114.5 Million USD | -50.693% |
| Intensity Therapeutics, Inc. | 8.31 Million USD | -1974.216% |
| Ocean Biomedical, Inc. | 2.48 Million USD | -6853.227% |
| CytomX Therapeutics, Inc. | 107.69 Million USD | -60.22% |
| Autolus Therapeutics plc | 196.72 Million USD | 12.287% |
| Mineralys Therapeutics, Inc. | 84.65 Million USD | -103.827% |
| EyePoint Pharmaceuticals, Inc. | 116.45 Million USD | -48.175% |
| Eterna Therapeutics Inc. | 19.38 Million USD | -790.234% |
| Adaptive Biotechnologies Corporation | 321.75 Million USD | 46.371% |
| GRI Bio, Inc. | 11.33 Million USD | -1422.983% |
| Xenetic Biosciences, Inc. | 7.05 Million USD | -2345.597% |
| Tenaya Therapeutics, Inc. | 131.19 Million USD | -31.527% |
| IGM Biosciences, Inc. | 265.59 Million USD | 35.03% |
| INmune Bio, Inc. | 29.89 Million USD | -477.181% |
| SAB Biotherapeutics, Inc. | 40.31 Million USD | -328.022% |
| Pasithea Therapeutics Corp. | 15.97 Million USD | -979.855% |
| Entero Therapeutics, Inc. | 15.74 Million USD | -996.169% |
| Milestone Pharmaceuticals Inc. | 62.09 Million USD | -177.874% |
| X4 Pharmaceuticals, Inc. | 107.52 Million USD | -60.483% |
| Atara Biotherapeutics, Inc. | 275.69 Million USD | 37.411% |
| Coherus BioSciences, Inc. | 301.45 Million USD | 42.759% |
| Verastem, Inc. | 92.08 Million USD | -87.388% |
| Abeona Therapeutics Inc. | 17.93 Million USD | -861.893% |
| Pliant Therapeutics, Inc. | 185.72 Million USD | 7.092% |
| Tonix Pharmaceuticals Holding Corp. | 121.4 Million USD | -42.129% |
| Histogen Inc. | 14.27 Million USD | -1109.039% |
| Aprea Therapeutics, Inc. | 16.04 Million USD | -975.227% |
| Surrozen, Inc. | 18.55 Million USD | -830.21% |
| Organovo Holdings, Inc. | 14.91 Million USD | -1056.916% |
| Lixte Biotechnology Holdings, Inc. | 5.09 Million USD | -3289.902% |
| Ovid Therapeutics Inc. | 59.67 Million USD | -189.165% |
| Panbela Therapeutics, Inc. | 25.64 Million USD | -572.804% |
| CASI Pharmaceuticals, Inc. | 47 Million USD | -267.089% |
| Cadrenal Therapeutics, Inc. Common Stock | 7.63 Million USD | -2160.678% |
| Centessa Pharmaceuticals plc | 178.13 Million USD | 3.134% |
| Hepion Pharmaceuticals, Inc. | 48.44 Million USD | -256.164% |
| Arcturus Therapeutics Holdings Inc. | 245 Million USD | 29.571% |
| BioRestorative Therapies, Inc. | 15.36 Million USD | -1022.918% |
| Apollomics, Inc. | 54.14 Million USD | -218.718% |
| Amarin Corporation plc | 272.35 Million USD | 36.644% |
| Mesoblast Limited | 5.9 Million USD | -2823.653% |
| Turnstone Biologics Corp. | 78.33 Million USD | -120.269% |
| Kymera Therapeutics, Inc. | 244.12 Million USD | 29.316% |
| Synaptogenix, Inc. | 8.31 Million USD | -1975.5% |
| Tiziana Life Sciences Ltd | 14.58 Million USD | -1083.011% |
| Aurinia Pharmaceuticals Inc. | 253.05 Million USD | 31.812% |
| BriaCell Therapeutics Corp. | 33.33 Million USD | -417.713% |
| Monopar Therapeutics Inc. | 8.83 Million USD | -1853.906% |
| Exelixis, Inc. | 1.58 Billion USD | 89.125% |
| Better Therapeutics, Inc. | 38.26 Million USD | -350.98% |
| Nurix Therapeutics, Inc. | 232.05 Million USD | 25.639% |
| Apellis Pharmaceuticals, Inc. | 855.2 Million USD | 79.823% |
| NLS Pharmaceutics AG | 11.8 Million USD | -1361.447% |
| Dermata Therapeutics, Inc. | 8.04 Million USD | -2045.685% |
| Aridis Pharmaceuticals, Inc. | 29.99 Million USD | -475.314% |
| Gritstone bio, Inc. | 148.37 Million USD | -16.297% |
| Jasper Therapeutics, Inc. | 68.86 Million USD | -150.583% |
| TNF Pharmaceuticals, Inc. | 16.36 Million USD | -954.717% |
| Avid Bioservices, Inc. | 25.99 Million USD | -563.771% |
| Insmed Incorporated | 949.26 Million USD | 81.822% |
| Virpax Pharmaceuticals, Inc. | 15.68 Million USD | -999.785% |
| MediWound Ltd. | 18.86 Million USD | -814.533% |
| OmniAb, Inc. | 83.89 Million USD | -105.679% |
| Alector, Inc. | 248.8 Million USD | 30.646% |
| Seres Therapeutics, Inc. | 234.3 Million USD | 26.356% |
| Checkpoint Therapeutics, Inc. | 52.25 Million USD | -230.241% |
| Zai Lab Limited | 547.47 Million USD | 68.482% |
| Revance Therapeutics, Inc. | 398.65 Million USD | 56.716% |
| Aura Biosciences, Inc. | 84.99 Million USD | -103.026% |
| Lyell Immunopharma, Inc. | 247.13 Million USD | 30.179% |
| Immunic, Inc. | 99.22 Million USD | -73.905% |
| Tarsus Pharmaceuticals, Inc. | 159.01 Million USD | -8.516% |
| Veracyte, Inc. | 357.93 Million USD | 51.792% |
| InMed Pharmaceuticals Inc. | 9.01 Billion USD | 98.086% |
| FibroGen, Inc. | 398.11 Million USD | 56.657% |
| SeaStar Medical Holding Corporation | 14.21 Million USD | -1114.314% |
| Adial Pharmaceuticals, Inc. | 6.88 Million USD | -2405.159% |
| Sonnet BioTherapeutics Holdings, Inc. | 7.12 Million USD | -2321.562% |
| Jazz Pharmaceuticals plc | 3.25 Billion USD | 94.7% |
| Cyclacel Pharmaceuticals, Inc. | 25.87 Million USD | -566.927% |
| Amylyx Pharmaceuticals, Inc. | 316.54 Million USD | 45.488% |
| TG Therapeutics, Inc. | 198.47 Million USD | 13.06% |
| Galecto, Inc. | 35.62 Million USD | -384.335% |
| Calithera Biosciences, Inc. | 40.68 Million USD | -324.08% |
| Fortrea Holdings Inc. | 457.3 Million USD | 62.267% |
| KalVista Pharmaceuticals, Inc. | 54.27 Million USD | -217.908% |
| Aptevo Therapeutics Inc. | 28.87 Million USD | -497.528% |
| XBiotech Inc. | 37.51 Million USD | -360.021% |
| Jasper Therapeutics, Inc. | 68.86 Million USD | -150.583% |
| Lyra Therapeutics, Inc. | 20.64 Million USD | -735.653% |
| Foghorn Therapeutics Inc. | 142.06 Million USD | -21.465% |
| Y-mAbs Therapeutics, Inc. | 99.07 Million USD | -74.165% |
| Theravance Biopharma, Inc. | 110.71 Million USD | -55.853% |
| Ultragenyx Pharmaceutical Inc. | 958.24 Million USD | 81.993% |
| Metagenomi, Inc. Common Stock | 28.84 Million USD | -498.211% |
| Vaxxinity, Inc. | 56.05 Million USD | -207.852% |
| BioCryst Pharmaceuticals, Inc. | 430.64 Million USD | 59.931% |
| Gain Therapeutics, Inc. | 22.3 Million USD | -673.496% |
| Cartesian Therapeutics, Inc. | 110.86 Million USD | -55.641% |
| NexImmune, Inc. | 28.16 Million USD | -512.599% |
| Creative Medical Technology Holdings, Inc. | 5.53 Million USD | -3019.791% |
| Marker Therapeutics, Inc. | 17.89 Million USD | -864.392% |
| Regeneron Pharmaceuticals, Inc. | 2.81 Billion USD | 93.871% |
| Chemomab Therapeutics Ltd. | 25.45 Million USD | -577.772% |
| Scopus BioPharma Inc. | 11.71 Million USD | -1372.948% |
| RAPT Therapeutics, Inc. | 127.06 Million USD | -35.803% |
| Ainos, Inc. | 12.95 Million USD | -1232.189% |
| Pluri Inc. | 22.48 Million USD | -667.589% |
| Prothena Corporation plc | 282.4 Million USD | 38.899% |
| Adaptimmune Therapeutics plc | 200.02 Million USD | 13.732% |
| Celularity Inc. | 215.05 Million USD | 19.764% |
| Rallybio Corporation | 78.93 Million USD | -118.611% |
| Cue Biopharma, Inc. | 19.54 Million USD | -782.99% |
| MeiraGTx Holdings plc | 151.07 Million USD | -14.215% |
| Omeros Corporation | 94.75 Million USD | -82.113% |
| Humacyte, Inc. | 23.49 Million USD | -634.366% |
| Immunocore Holdings plc | 308.04 Million USD | 43.983% |
| Cocrystal Pharma, Inc. | 3.39 Million USD | -4990.088% |
| Cidara Therapeutics, Inc. | 86.86 Million USD | -98.646% |
| Blueprint Medicines Corporation | 722.86 Million USD | 76.129% |
| CalciMedica, Inc. | 21.81 Million USD | -690.915% |
| Cabaletta Bio, Inc. | 74.66 Million USD | -131.12% |
| Marinus Pharmaceuticals, Inc. | 160.54 Million USD | -7.483% |
| Scholar Rock Holding Corporation | 171.29 Million USD | -0.735% |
| Sana Biotechnology, Inc. | 294.94 Million USD | 41.495% |
| Pulmatrix, Inc. | 22.03 Million USD | -682.984% |
| Elicio Therapeutics, Inc. | 34.57 Million USD | -399.072% |
| Vigil Neuroscience, Inc. | 88.86 Million USD | -94.173% |
| Intellia Therapeutics, Inc. | 551.56 Million USD | 68.716% |
| Adlai Nortye Ltd. American Depositary Shares | 72.55 Million USD | -137.838% |
| Cytokinetics, Incorporated | 173.61 Million USD | 0.609% |
| Eloxx Pharmaceuticals, Inc. | 34.41 Million USD | -401.334% |
| Nutriband Inc. | 5.73 Million USD | -2909.297% |
| Protara Therapeutics, Inc. | 43.61 Million USD | -295.648% |
| Vor Biopharma Inc. | 126.03 Million USD | -36.909% |
| Roivant Sciences Ltd. | 1.18 Billion USD | 85.49% |
| Evogene Ltd. | 27.79 Million USD | -520.921% |
| ProKidney Corp. | 151.52 Million USD | -13.88% |
| Applied Therapeutics, Inc. | 74.17 Million USD | -132.631% |
| Hoth Therapeutics, Inc. | 7.69 Million USD | -2143.221% |
| BridgeBio Pharma, Inc. | 614.22 Million USD | 71.907% |
| CorMedix Inc. | 48.95 Million USD | -252.455% |
| BioLineRx Ltd. | 50.8 Million USD | -239.66% |
| Tango Therapeutics, Inc. | 150.7 Million USD | -14.502% |
| Galectin Therapeutics Inc. | 38.07 Million USD | -353.231% |
| Atai Life Sciences N.V. | 125.78 Million USD | -37.182% |
| Renovaro Biosciences Inc. | 81.63 Million USD | -111.361% |
| Aerovate Therapeutics, Inc. | 81.4 Million USD | -111.959% |
| Zentalis Pharmaceuticals, Inc. | 252.55 Million USD | 31.676% |
| Sagimet Biosciences Inc. | 32.74 Million USD | -427.043% |
| MediciNova, Inc. | 10.9 Million USD | -1483.026% |
| Praxis Precision Medicines, Inc. | 128.82 Million USD | -33.95% |
| Cardio Diagnostics Holdings, Inc. | 7.25 Million USD | -2276.933% |
| GeoVax Labs, Inc. | 6.02 Million USD | -2765.311% |
| Axsome Therapeutics, Inc. | 476.36 Million USD | 63.777% |
| Biomea Fusion, Inc. | 126.13 Million USD | -36.801% |
| PTC Therapeutics, Inc. | 1.31 Billion USD | 86.846% |
| Mereo BioPharma Group plc | 35.84 Million USD | -381.43% |
| Cullinan Oncology, Inc. | 191.08 Million USD | 9.7% |
| Syndax Pharmaceuticals, Inc. | 229.95 Million USD | 24.962% |
| Absci Corporation | 73.66 Million USD | -134.238% |
| NRx Pharmaceuticals, Inc. | 27.58 Million USD | -525.604% |
| 4D Molecular Therapeutics, Inc. | 133.59 Million USD | -29.167% |
| Dyne Therapeutics, Inc. | 242.16 Million USD | 28.744% |
| Kiniksa Pharmaceuticals, Ltd. | 262.04 Million USD | 34.152% |
| Ventyx Biosciences, Inc. | 207.99 Million USD | 17.039% |
| Allakos Inc. | 196.05 Million USD | 11.987% |
| Imunon, Inc. | 20.31 Million USD | -749.583% |
| Fulcrum Therapeutics, Inc. | 113.46 Million USD | -52.071% |
| Corcept Therapeutics Incorporated | 368.61 Million USD | 53.188% |
| BioAtla, Inc. | 129.68 Million USD | -33.054% |
| NLS Pharmaceutics AG | 11.8 Million USD | -1361.447% |
| Bio-Path Holdings, Inc. | 15.84 Million USD | -989.15% |
| Allogene Therapeutics, Inc. | 84.91 Million USD | -103.201% |
| Larimar Therapeutics, Inc. | 41.75 Million USD | -313.224% |
| XOMA Corporation | 46.46 Million USD | -271.379% |
| Kezar Life Sciences, Inc. | 111.17 Million USD | -55.215% |
| Cara Therapeutics, Inc. | 142.46 Million USD | -21.122% |
| aTyr Pharma, Inc. | 12.97 Million USD | -1229.486% |
| Aligos Therapeutics, Inc. | 103.65 Million USD | -66.468% |
| Akero Therapeutics, Inc. | 172.87 Million USD | 0.183% |
| Viridian Therapeutics, Inc. | 254.76 Million USD | 32.269% |
| Eliem Therapeutics, Inc. | 37.4 Million USD | -361.276% |
| EyeGate Pharmaceuticals, Inc. | 8.22 Million USD | -1997.968% |
| Akari Therapeutics, Plc | 16.8 Million USD | -926.74% |
| Tevogen Bio Holdings Inc. | 2.27 Million USD | -7488.227% |
| Halozyme Therapeutics, Inc. | 299.31 Million USD | 42.351% |
| Lexaria Bioscience Corp. | 6.72 Million USD | -2464.436% |
| UroGen Pharma Ltd. | 138.88 Million USD | -24.24% |
| Sutro Biopharma, Inc. | 243 Million USD | 28.993% |
| ZIVO Bioscience, Inc. | 7.27 Million USD | -2272.0% |
| Orgenesis Inc. | 45.75 Million USD | -277.11% |
| Entera Bio Ltd. | 8.86 Million USD | -1847.562% |
| GH Research PLC | 41.22 Million USD | -318.597% |
| Lisata Therapeutics, Inc. | 25.7 Million USD | -571.207% |
| Reneo Pharmaceuticals, Inc. | 83.05 Million USD | -107.764% |
| Xencor, Inc. | 306.97 Million USD | 43.789% |
| 60 Degrees Pharmaceuticals, Inc. | 4.93 Million USD | -3397.523% |
| Replimune Group, Inc. | 234.77 Million USD | 26.502% |
| Coeptis Therapeutics Holdings, Inc. | 20.48 Million USD | -742.142% |
| Vanda Pharmaceuticals Inc. | 191.79 Million USD | 10.033% |
| Lexaria Bioscience Corp. | 6.72 Million USD | -2464.436% |
| Portage Biotech Inc. | 18.19 Million USD | -848.151% |
| Cardio Diagnostics Holdings, Inc. | 7.25 Million USD | -2276.933% |
| Olema Pharmaceuticals, Inc. | 104.96 Million USD | -64.398% |
| OncoCyte Corporation | 25.63 Million USD | -573.066% |
| Qualigen Therapeutics, Inc. | 6.09 Million USD | -2730.793% |
| Processa Pharmaceuticals, Inc. | 11.45 Million USD | -1406.093% |
| Purple Biotech Ltd. | -22.46 Million USD | 868.033% |
| CollPlant Biotechnologies Ltd. | 16.48 Million USD | -947.051% |
| scPharmaceuticals Inc. | 65.17 Million USD | -164.743% |
| ProMIS Neurosciences, Inc. | 8.45 Million USD | -1941.398% |
| HilleVax, Inc. | 133.34 Million USD | -29.404% |
| NeuroSense Therapeutics Ltd. | 10.28 Million USD | -1577.725% |
| Tharimmune, Inc. | 9.45 Million USD | -1724.96% |
| Genprex, Inc. | 31.06 Million USD | -455.54% |
| Neumora Therapeutics, Inc. Common Stock | 187.52 Million USD | 7.984% |
| Atossa Therapeutics, Inc. | 31.37 Million USD | -449.938% |
| XTL Biopharmaceuticals Ltd. | 765 Thousand USD | -22456.078% |
| Virios Therapeutics, Inc. | 5.44 Million USD | -3067.919% |
| OKYO Pharma Limited | 8243.57 USD | -2093095.06% |
| Savara Inc. | 15.74 Million USD | -995.929% |
| Curis, Inc. | 58.35 Million USD | -195.697% |
| Daré Bioscience, Inc. | 33.6 Million USD | -413.41% |
| Carmell Therapeutics Corporation | 5.09 Million USD | -3288.403% |
| Titan Pharmaceuticals, Inc. | 7.46 Million USD | -2212.746% |
| Achieve Life Sciences, Inc. | 27.02 Million USD | -538.569% |
| BeiGene, Ltd. | 3.28 Billion USD | 94.75% |
| Kiromic BioPharma, Inc. | 19.93 Million USD | -765.396% |
| Revolution Medicines, Inc. Warrant | 498.76 Million USD | 65.404% |
| Protagonist Therapeutics, Inc. | 153.65 Million USD | -12.302% |
| Erasca, Inc. | 141.52 Million USD | -21.925% |
| bluebird bio, Inc. | 240.23 Million USD | 28.172% |
| Protagenic Therapeutics, Inc. | 4.52 Million USD | -3711.685% |
| BioMarin Pharmaceutical Inc. | 1.74 Billion USD | 90.119% |
| DBV Technologies S.A. | 92.16 Million USD | -87.233% |
| Protagenic Therapeutics, Inc. | 4.52 Million USD | -3711.685% |
| Moderna, Inc. | 6.39 Billion USD | 97.301% |
| Vincerx Pharma, Inc. | 42.6 Million USD | -304.971% |
| Fresh Tracks Therapeutics, Inc. | 14.36 Million USD | -1101.128% |
| Molecular Templates, Inc. | 63.09 Million USD | -173.5% |
| Acrivon Therapeutics, Inc. Common Stock | 66.7 Million USD | -158.698% |
| Travere Therapeutics, Inc. | 472 Million USD | 63.442% |
| Monte Rosa Therapeutics, Inc. | 143.31 Million USD | -20.405% |
| Spruce Biosciences, Inc. | 62.08 Million USD | -177.945% |
| Celldex Therapeutics, Inc. | 43.41 Million USD | -297.462% |
| Cogent Biosciences, Inc. | 208.13 Million USD | 17.093% |
| MacroGenics, Inc. | 217.21 Million USD | 20.561% |
| RenovoRx, Inc. | 11.39 Million USD | -1414.163% |
| Adicet Bio, Inc. | 152.03 Million USD | -13.494% |
| Prime Medicine, Inc. | 186.63 Million USD | 7.547% |
| Aditxt, Inc. | 25.95 Million USD | -564.928% |
| Adagene Inc. | 41.83 Million USD | -312.499% |
| Estrella Immunopharma, Inc. | 7.31 Million USD | -2260.488% |
| Quantum-Si incorporated | 111.65 Million USD | -54.537% |
| Maravai LifeSciences Holdings, Inc. | 171.85 Million USD | -0.41% |
| Acurx Pharmaceuticals, Inc. | 14.57 Million USD | -1083.679% |
| Voyager Therapeutics, Inc. | 35.82 Million USD | -381.698% |
| SciSparc Ltd. | 9.01 Million USD | -1814.926% |
| Vericel Corporation | 142.04 Million USD | -21.483% |
| Revelation Biosciences, Inc. | 8.65 Million USD | -1893.308% |
| Minerva Neurosciences, Inc. | 23.08 Million USD | -647.356% |
| Generation Bio Co. | 144.46 Million USD | -19.442% |
| Astria Therapeutics, Inc. | 83.03 Million USD | -107.821% |
| Black Diamond Therapeutics, Inc. | 86.46 Million USD | -99.577% |
| Arcutis Biotherapeutics, Inc. | 295.72 Million USD | 41.65% |
| Invivyd, Inc. | 205.75 Million USD | 16.136% |
| Relay Therapeutics, Inc. | 72.15 Million USD | -139.13% |
| Quoin Pharmaceuticals, Ltd. | 9.37 Million USD | -1739.888% |
| Spero Therapeutics, Inc. | 75.25 Million USD | -129.295% |
| Artelo Biosciences, Inc. | 10.28 Million USD | -1577.399% |
| 2seventy bio, Inc. | 289.88 Million USD | 40.475% |
| ADMA Biologics, Inc. | 66.58 Million USD | -159.145% |
| Clene Inc. | 41.07 Million USD | -320.115% |
| Capricor Therapeutics, Inc. | 12.8 Million USD | -1247.248% |
| Boundless Bio, Inc. Common Stock | 54.79 Million USD | -214.903% |
| GeoVax Labs, Inc. | 6.02 Million USD | -2765.311% |
| Recursion Pharmaceuticals, Inc. | 352.04 Million USD | 50.986% |
| Citius Pharmaceuticals, Inc. | 36.73 Million USD | -369.765% |
| Contineum Therapeutics, Inc. Class A Common Stock | 33.72 Million USD | -411.605% |
| Relmada Therapeutics, Inc. | 103.7 Million USD | -66.394% |
| Finch Therapeutics Group, Inc. | 32.58 Million USD | -429.485% |
| ALX Oncology Holdings Inc. | 170.27 Million USD | -1.337% |
| Vir Biotechnology, Inc. | 767.72 Million USD | 77.524% |
| Evaxion Biotech A/S | 22.27 Million USD | -674.827% |
| Ocular Therapeutix, Inc. | 135.54 Million USD | -27.305% |
| Verve Therapeutics, Inc. | 234.88 Million USD | 26.536% |
| Trevena, Inc. | 38.41 Million USD | -349.207% |
| Surrozen, Inc. | 18.55 Million USD | -830.21% |
| Tyra Biosciences, Inc. | 79.94 Million USD | -115.841% |
| Cingulate Inc. | 22.75 Million USD | -658.173% |
| Galmed Pharmaceuticals Ltd. | -7.49 Million USD | 2403.177% |
| Unity Biotechnology, Inc. | 44.66 Million USD | -286.312% |
| Tenax Therapeutics, Inc. | 8.23 Million USD | -1995.643% |
| Terns Pharmaceuticals, Inc. | 102.55 Million USD | -68.25% |
| ACADIA Pharmaceuticals Inc. | 754.08 Million USD | 77.117% |
| Connect Biopharma Holdings Limited | 62.07 Million USD | -177.981% |
| Clearmind Medicine Inc. | 8.74 Million USD | -1873.997% |
| Kronos Bio, Inc. | 128.11 Million USD | -34.684% |
| Bolt Biotherapeutics, Inc. | 84.07 Million USD | -105.246% |
| CERo Therapeutics Holdings, Inc. | 2.93 Million USD | -5783.221% |
| Viking Therapeutics, Inc. | 100.82 Million USD | -71.139% |
| Statera Biopharma, Inc. | 28.82 Million USD | -498.533% |
| ImmunityBio, Inc. | 362.87 Million USD | 52.448% |
| Korro Bio, Inc. | 84.53 Million USD | -104.124% |
| Kineta, Inc. | 21.15 Million USD | -715.627% |
| BioVie Inc. | 31.95 Million USD | -440.072% |
| Codexis, Inc. | 66.51 Million USD | -159.409% |
| Celularity Inc. | 215.05 Million USD | 19.764% |
| Crinetics Pharmaceuticals, Inc. | 226.62 Million USD | 23.858% |
| Celcuity Inc. | 66.23 Million USD | -160.536% |
| Virax Biolabs Group Limited | 6.54 Million USD | -2535.594% |
| Cibus, Inc. | 320.3 Million USD | 46.128% |
| Eledon Pharmaceuticals, Inc. | 43 Million USD | -301.288% |
| eFFECTOR Therapeutics, Inc. | 33.84 Million USD | -409.851% |
| IN8bio, Inc. | 30.33 Million USD | -468.791% |
| Kodiak Sciences Inc. | 277.32 Million USD | 37.778% |
| Annexon, Inc. | 143.72 Million USD | -20.06% |
| Adverum Biotechnologies, Inc. | 127.59 Million USD | -35.24% |
| Assembly Biosciences, Inc. | 22.9 Million USD | -653.215% |
| Avalo Therapeutics, Inc. | 640 Thousand USD | -26861.563% |
| Ionis Pharmaceuticals, Inc. | 779.58 Million USD | 77.866% |
| Eyenovia, Inc. | 25.4 Million USD | -579.174% |
| Puma Biotechnology, Inc. | 140.31 Million USD | -22.976% |
| Conduit Pharmaceuticals Inc. | 5.56 Million USD | -3002.373% |
| Xilio Therapeutics, Inc. | 79.13 Million USD | -118.056% |
| Arcellx, Inc. | 200.19 Million USD | 13.809% |
| Cardiff Oncology, Inc. | 45.9 Million USD | -275.935% |
| Enanta Pharmaceuticals, Inc. | 216.41 Million USD | 20.266% |
| Regulus Therapeutics Inc. | 9.95 Million USD | -1632.992% |
| Moolec Science SA | 52.75 Million USD | -227.113% |
| Acumen Pharmaceuticals, Inc. | 61.13 Million USD | -182.237% |
| Geron Corporation | 70.44 Million USD | -144.962% |
| LAVA Therapeutics N.V. | 46.54 Million USD | -270.765% |
| Royalty Pharma plc | 862.4 Million USD | 79.992% |
| Atea Pharmaceuticals, Inc. | 94.07 Million USD | -83.428% |
| Greenwich LifeSciences, Inc. | 9.32 Million USD | -1749.876% |
| TFF Pharmaceuticals, Inc. | 22.62 Million USD | -662.551% |
| Mersana Therapeutics, Inc. | 207.81 Million USD | 16.966% |
| Humacyte, Inc. | 23.49 Million USD | -634.366% |
| Structure Therapeutics Inc. | 102.77 Million USD | -67.895% |
| 89bio, Inc. | 151.2 Million USD | -14.12% |
| PMV Pharmaceuticals, Inc. | 80.13 Million USD | -115.337% |
| Avenue Therapeutics, Inc. | 14.54 Million USD | -1086.754% |
| Genelux Corporation | 24.33 Million USD | -609.077% |
| Trevi Therapeutics, Inc. | 33.92 Million USD | -408.664% |
| Lexicon Pharmaceuticals, Inc. | 172.86 Million USD | 0.182% |
| Notable Labs, Ltd. | 14.77 Million USD | -1068.274% |
| Liquidia Corporation | 87.98 Million USD | -96.12% |
| Mustang Bio, Inc. | 48.5 Million USD | -255.774% |
| Immunovant, Inc. | 282.7 Million USD | 38.964% |
| Quantum-Si incorporated | 111.65 Million USD | -54.537% |
| Arbutus Biopharma Corporation | 22.54 Million USD | -665.41% |
| DiaMedica Therapeutics Inc. | 21.26 Million USD | -711.37% |
| Vera Therapeutics, Inc. | 102.01 Million USD | -69.151% |
| Acasti Pharma Inc. | 11.3 Million USD | -1426.891% |
| MiNK Therapeutics, Inc. | 22.92 Million USD | -652.817% |
| Pasithea Therapeutics Corp. | 15.97 Million USD | -979.855% |
| Xenon Pharmaceuticals Inc. | 46.54 Million USD | -270.749% |
| Elevai Labs, Inc. Common Stock | 1.13 Million USD | -15108.623% |
| NeuroBo Pharmaceuticals, Inc. | 15.88 Million USD | -986.202% |
| Tempest Therapeutics, Inc. | 29.15 Million USD | -491.81% |
| Soleno Therapeutics, Inc. | 41.38 Million USD | -316.958% |
| PepGen Inc. | 84.76 Million USD | -103.565% |
| Moleculin Biotech, Inc. | 29.63 Million USD | -482.343% |
| United Therapeutics Corporation | 885.1 Million USD | 80.505% |
| Nuvectis Pharma, Inc. | 22.89 Million USD | -653.61% |
| Solid Biosciences Inc. | 104.31 Million USD | -65.416% |
| BriaCell Therapeutics Corp. | 32.72 Million USD | -427.276% |
| Immuneering Corporation | 58.41 Million USD | -195.404% |
| Lixte Biotechnology Holdings, Inc. | 5.09 Million USD | -3289.902% |
| Silo Pharma, Inc. | 3.92 Million USD | -4299.805% |
| Belite Bio, Inc | 31.66 Million USD | -444.884% |
| XOMA Corporation | 46.46 Million USD | -271.379% |
| ARS Pharmaceuticals, Inc. | 67.55 Million USD | -155.446% |
| Bionomics Limited | 17.89 Billion USD | 99.036% |
| Apogee Therapeutics, Inc. | 93 Million USD | -85.536% |
| Alpha Tau Medical Ltd. | -35.68 Million USD | 583.615% |
| uniQure N.V. | 285.08 Million USD | 39.473% |
| Cassava Sciences, Inc. | 105.95 Million USD | -62.853% |
| Estrella Immunopharma, Inc. | 7.31 Million USD | -2260.488% |
| Poseida Therapeutics, Inc. | 194.2 Million USD | 11.149% |
| Forte Biosciences, Inc. | 32.47 Million USD | -431.311% |
| Anebulo Pharmaceuticals, Inc. | 8.3 Million USD | -1976.773% |
| Enlivex Therapeutics Ltd. | 29.39 Million USD | -487.018% |
| Conduit Pharmaceuticals Inc. | 5.56 Million USD | -3002.373% |
| SeaStar Medical Holding Corporation | 14.21 Million USD | -1114.314% |
| FibroBiologics, Inc. Common Stock | 8.88 Million USD | -1841.208% |
| Altimmune, Inc. | 30.55 Million USD | -464.714% |
| Amicus Therapeutics, Inc. | 427.65 Million USD | 59.651% |
| Alpha Tau Medical Ltd. | -35.68 Million USD | 583.615% |
| Compugen Ltd. | 43.97 Million USD | -292.427% |
| Peak Bio, Inc. | 1249.13 USD | -13813834.498% |
| Zevra Therapeutics, Inc. | 74.12 Million USD | -132.804% |
| Benitec Biopharma Inc. | 22.38 Million USD | -670.95% |
| Spyre Therapeutics, Inc. | 243.18 Million USD | 29.045% |
| NKGen Biotech, Inc. Common Stock | 28.54 Million USD | -504.541% |
| Zura Bio Limited | 62.63 Million USD | -175.478% |
| PolyPid Ltd. | 21.04 Million USD | -719.929% |
| Aileron Therapeutics, Inc. | 16.27 Million USD | -960.174% |
| NKGen Biotech, Inc. Warrants | 28.54 Million USD | -504.541% |
| Instil Bio, Inc. | 85.78 Million USD | -101.147% |
| argenx SE | 1.53 Billion USD | 88.748% |
| Immunome, Inc. | 122.82 Million USD | -40.493% |
| Compass Therapeutics, Inc. | 48.47 Million USD | -255.98% |
| Verona Pharma plc | 67.15 Million USD | -156.963% |
| enGene Holdings Inc. Warrants | 25.88 Million USD | -566.618% |
| Shattuck Labs, Inc. | 93.61 Million USD | -84.325% |
| CervoMed Inc. | 14.95 Million USD | -1053.608% |
| LENZ Therapeutics, Inc. | 70.7 Million USD | -144.055% |
| Plus Therapeutics, Inc. | 8.54 Million USD | -1919.593% |
| Dianthus Therapeutics, Inc. | 51 Million USD | -238.341% |
| Moolec Science SA | 52.75 Million USD | -227.113% |
| Enveric Biosciences, Inc. | 16.44 Million USD | -949.06% |
| Inovio Pharmaceuticals, Inc. | 132.55 Million USD | -30.175% |
| AnaptysBio, Inc. | 181.56 Million USD | 4.965% |
| Design Therapeutics, Inc. | 78.19 Million USD | -120.686% |
| Leap Therapeutics, Inc. | 87.04 Million USD | -98.245% |
| NeurAxis, Inc. | 8.82 Million USD | -1856.129% |
| Seelos Therapeutics, Inc. | 12.58 Million USD | -1271.108% |
| Lumos Pharma, Inc. | 38.66 Million USD | -346.28% |
| Achilles Therapeutics plc | 75.25 Million USD | -129.292% |
| enGene Holdings Inc. Common Stock | 25.88 Million USD | -566.618% |
| 180 Life Sciences Corp. | 13.47 Million USD | -1180.312% |
| Opiant Pharmaceuticals, Inc. | 26.5 Million USD | -551.087% |
| CERo Therapeutics Holdings, Inc. | 2.93 Million USD | -5783.221% |
| Nutriband Inc. | 5.73 Million USD | -2909.297% |
| ORIC Pharmaceuticals, Inc. | 110.78 Million USD | -55.763% |
| CG Oncology, Inc. Common stock | 55.65 Million USD | -210.053% |
| Fractyl Health, Inc. Common Stock | 50.87 Million USD | -239.146% |
| Rani Therapeutics Holdings, Inc. | 66.09 Million USD | -161.054% |
| MoonLake Immunotherapeutics | 54.12 Million USD | -218.818% |
| Palisade Bio, Inc. | 13.32 Million USD | -1195.45% |
| Tourmaline Bio, Inc. | 45.4 Million USD | -280.0% |
| Beam Therapeutics Inc. | 554.19 Million USD | 68.864% |
| Neurogene Inc. | 55.58 Million USD | -210.444% |
| Mirum Pharmaceuticals, Inc. | 248.48 Million USD | 30.559% |
| AEON Biopharma, Inc. | 48.42 Million USD | -256.303% |
| CARGO Therapeutics, Inc. Common Stock | 96.71 Million USD | -78.424% |
| Sesen Bio, Inc. | 78.38 Million USD | -120.148% |
| Enliven Therapeutics, Inc. | 83.52 Million USD | -106.58% |
| Kiora Pharmaceuticals, Inc. | 12.58 Million USD | -1270.902% |
| Iovance Biotherapeutics, Inc. | 450.99 Million USD | 61.739% |
| Taysha Gene Therapies, Inc. | 87.89 Million USD | -96.33% |
| Athira Pharma, Inc. | 125.46 Million USD | -37.53% |
| Vaccinex, Inc. | 23.45 Million USD | -635.681% |
| HCW Biologics Inc. | 21.02 Million USD | -720.61% |
| XOMA Corporation | 46.46 Million USD | -271.379% |
| Nektar Therapeutics | 190.9 Million USD | 9.612% |
| Arvinas, Inc. | 480 Million USD | 64.051% |
| Tevogen Bio Holdings Inc. | 2.27 Million USD | -7488.227% |
| Merus N.V. | 200.49 Million USD | 13.936% |
| Omega Therapeutics, Inc. | 103.35 Million USD | -66.953% |
| Quince Therapeutics, Inc. | 34.62 Million USD | -398.423% |
| Rezolute, Inc. | 70.38 Million USD | -145.15% |
| Clene Inc. | 41.07 Million USD | -320.115% |
| Indaptus Therapeutics, Inc. | 16.37 Million USD | -953.541% |
| BeyondSpring Inc. | 24.86 Million USD | -593.963% |
| Synlogic, Inc. | 58.53 Million USD | -194.803% |
| Allarity Therapeutics, Inc. | 17.89 Million USD | -864.42% |
| Phio Pharmaceuticals Corp. | 4.49 Million USD | -3741.362% |
| Peak Bio, Inc. | 1249.13 USD | -13813834.498% |
| Werewolf Therapeutics, Inc. | 60.44 Million USD | -185.468% |
| Krystal Biotech, Inc. | 160.42 Million USD | -7.56% |
| Karyopharm Therapeutics Inc. | 270.63 Million USD | 36.24% |
| SpringWorks Therapeutics, Inc. | 348.03 Million USD | 50.421% |
| Lipella Pharmaceuticals Inc. | 2.15 Million USD | -7900.708% |
| MannKind Corporation | 125.59 Million USD | -37.387% |
| Ikena Oncology, Inc. | 84.57 Million USD | -104.02% |
| Cyclerion Therapeutics, Inc. | 9.64 Million USD | -1688.68% |
| Gyre Therapeutics, Inc. | 89.6 Million USD | -92.58% |
| Gossamer Bio, Inc. | 183.75 Million USD | 6.098% |
| CohBar, Inc. | 12.38 Million USD | -1292.879% |
| Cognition Therapeutics, Inc. | 50.72 Million USD | -240.182% |
| NRx Pharmaceuticals, Inc. | 27.58 Million USD | -525.604% |
| Legend Biotech Corporation | 583.14 Million USD | 70.41% |
| Mural Oncology plc | 192.07 Million USD | 10.161% |
| Biora Therapeutics, Inc. | 67.14 Million USD | -156.979% |
| PaxMedica, Inc. Common Stock | 16.14 Million USD | -968.759% |
| Disc Medicine, Inc. | 91.12 Million USD | -89.36% |
| Champions Oncology, Inc. | 28.11 Million USD | -513.853% |
| REGENXBIO Inc. | 321.15 Million USD | 46.271% |
| Ensysce Biosciences, Inc. | 5.36 Million USD | -3118.55% |
| Anavex Life Sciences Corp. | 55.75 Million USD | -209.481% |
| Cellectar Biosciences, Inc. | 38.96 Million USD | -342.893% |
| Edgewise Therapeutics, Inc. | 114.35 Million USD | -50.891% |
| Vaxart, Inc. | 90.72 Million USD | -90.192% |
| PharmaCyte Biotech, Inc. | 8.52 Million USD | -1925.28% |
| Aldeyra Therapeutics, Inc. | 42.79 Million USD | -303.219% |
| Cellectis S.A. | 97.32 Million USD | -77.306% |
| Longeveron Inc. | 21.25 Million USD | -712.019% |
| Repare Therapeutics Inc. | 167.35 Million USD | -3.105% |
| Sarepta Therapeutics, Inc. | 1.36 Billion USD | 87.32% |
| Inozyme Pharma, Inc. | 75.64 Million USD | -128.11% |
| Revolution Medicines, Inc. | 498.76 Million USD | 65.404% |
| Nymox Pharmaceutical Corporation | 6.65 Million USD | -2494.017% |
| Third Harmonic Bio, Inc. | 43.95 Million USD | -292.579% |
| ArriVent BioPharma, Inc. Common Stock | 74.59 Million USD | -131.337% |
| AN2 Therapeutics, Inc. | 69.63 Million USD | -147.798% |
| Anixa Biosciences, Inc. | 11.06 Million USD | -1460.163% |
| Vertex Pharmaceuticals Incorporated | 4.77 Billion USD | 96.386% |
| Denali Therapeutics Inc. | 527.23 Million USD | 67.272% |
| Revelation Biosciences, Inc. | 8.65 Million USD | -1893.308% |
| Veru Inc. | 101.34 Million USD | -70.259% |
| Corvus Pharmaceuticals, Inc. | 23.4 Million USD | -637.19% |
| Cingulate Inc. | 22.75 Million USD | -658.173% |
| Passage Bio, Inc. | 108.38 Million USD | -59.199% |
| Context Therapeutics Inc. | 25.07 Million USD | -588.217% |
| Exicure, Inc. | 14.07 Million USD | -1125.874% |
| Day One Biopharmaceuticals, Inc. | 206.06 Million USD | 16.262% |
| Oramed Pharmaceuticals Inc. | 43.3 Million USD | -298.499% |
| Scinai Immunotherapeutics Ltd. | 9.17 Million USD | -1780.228% |
| Rhythm Pharmaceuticals, Inc. | 252.48 Million USD | 31.657% |
| Nuvalent, Inc. | 149.49 Million USD | -15.427% |
| ABVC BioPharma, Inc. | 8.06 Million USD | -2039.037% |
| Carisma Therapeutics, Inc. | 103.65 Million USD | -66.478% |
| Unicycive Therapeutics, Inc. | 21.44 Million USD | -704.485% |
| OmniAb, Inc. | 83.89 Million USD | -105.679% |
| Anew Medical, Inc. | 1.3 Million USD | -13164.803% |
| Fennec Pharmaceuticals Inc. | 32.76 Million USD | -426.657% |
| Lipocine Inc. | 15.08 Million USD | -1044.247% |
| Lexeo Therapeutics, Inc. Common Stock | 68.51 Million USD | -151.856% |
| Nautilus Biotechnology, Inc. | 76.15 Million USD | -126.592% |
| SAB Biotherapeutics, Inc. | 40.31 Million USD | -328.022% |
| G1 Therapeutics, Inc. | 114.84 Million USD | -50.252% |
| Bellerophon Therapeutics, Inc. | 22.38 Million USD | -670.881% |
| Sage Therapeutics, Inc. | 664.14 Million USD | 74.019% |
| Ocugen, Inc. | 71.56 Million USD | -141.108% |
| Mind Medicine (MindMed) Inc. | 93.86 Million USD | -83.83% |
| Q32 Bio Inc. | 92.68 Million USD | -86.183% |
| Brainstorm Cell Therapeutics Inc. | 21.17 Million USD | -714.933% |
| Alumis Inc. Common Stock | 158.17 Million USD | -9.091% |
| Equillium, Inc. | 50.6 Million USD | -240.975% |
| Kyverna Therapeutics, Inc. | 62.4 Million USD | -176.502% |
| Coya Therapeutics, Inc. | 13.9 Million USD | -1140.9% |
| CNS Pharmaceuticals, Inc. | 18.86 Million USD | -814.673% |
| Galera Therapeutics, Inc. | 46.95 Million USD | -267.519% |
| Evelo Biosciences, Inc. | 108.46 Million USD | -59.086% |
| Comera Life Sciences Holdings, Inc. | 12.39 Million USD | -1292.381% |
| Dominari Holdings Inc. | 23.83 Million USD | -623.952% |
| Edesa Biotech, Inc. | 9.22 Million USD | -1770.959% |
| vTv Therapeutics Inc. | 11.9 Million USD | -1349.181% |
| Bio-Techne Corporation | 563.03 Million USD | 69.353% |
| Agios Pharmaceuticals, Inc. | 408.8 Million USD | 57.791% |
| Harmony Biosciences Holdings, Inc. | 268.75 Million USD | 35.795% |
| Prelude Therapeutics Incorporated | 132.27 Million USD | -30.449% |
| Candel Therapeutics, Inc. | 14.41 Million USD | -1097.377% |
| iTeos Therapeutics, Inc. | 163.69 Million USD | -5.411% |
| Nkarta, Inc. | 131.65 Million USD | -31.07% |
| BioCardia, Inc. | 12.12 Million USD | -1323.595% |
| Iterum Therapeutics plc | 47.46 Million USD | -263.516% |